Antibody response to revaccination among adult non-responders to primary Hepatitis B vaccination in China

References

• Kane MA. Global programme for control of hepatitis B infection. Vaccine 1995; 13(Supply 1):S47-9; PMID:7571830; http://dx.doi.org/10.1016/0264-410X(95)80050-N
   PubMedGoogle Scholar
• Chen DS. Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. J Hepatol 2009; 50(4):805-16; PMID:19231008; http://dx.doi.org/10.1016/j.jhep.2009.01.002
   PubMed Web of Science ®Google Scholar
• Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, et al. Epidemiological serosurvey of Hepatitis B in China— Declining HBV prevalence due to Hepatitis B vaccination. Vaccine 2009; 27(47):6550-7; PMID:19729084; http://dx.doi.org/10.1016/j.vaccine.2009.08.048
   PubMed Web of Science ®Google Scholar
• Cui FQ; Chinese Prevention Medicine Association; National Immunization Program, Chinese Center for Disease Control and Prevention. Technical guide for adult hepatitis B immunization in China. Zhonghua Liu Xing Bing Xue Za Zhi 2011 Dec; 32(12):1199-203; PMID:22336599
   PubMedGoogle Scholar
• Greenberg DP. Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunogenicity studies. Pediatr Infect Dis J 1993; 12(5):438-45; PMID:8327313; http://dx.doi.org/10.1097/00006454-199305000-00037
   PubMed Web of Science ®Google Scholar
• Greenberg DP, Vadheim CM, Wong VK, Marcy SM, Partridge S, Greene T, Chiu CY, Margolis HS, Ward JI. Comparative safety and immunogenicity of two recombinant hepatitis B vaccines administered to infants at two, four and six months of age. Pediatr Infect Dis J 1996 Jul; (7):590-6; PMID:8823852; http://dx.doi.org/10.1097/00006454-199607000-00006
   PubMed Web of Science ®Google Scholar
• André FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989 Sep 4; 87(3A):14S-20S; PMID:2528292
   PubMedGoogle Scholar
• Zajac BA, West DJ, McAleer WJ, Scolnick EM. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect 1986 Jul; 13(Suppl A):39-45; PMID:2943814
   PubMed Web of Science ®Google Scholar
• Zhang W, Han L, Lin C, Wang H, Pang X, Li L, Gao P, Lin H, Gong X, Tang Y, et al. Surface antibody and cytokine response to recombinant Chinese hamster ovary cell (CHO) hepatitis B vaccine. Vaccine 2011 Aug 26; 29(37):6276-82; PMID:21722684; http://dx.doi.org/10.1016/j.vaccine.2011.06.045
   PubMed Web of Science ®Google Scholar
• Jiaye L, Bingyu Y, Li Z, Jingjing L, Yi F, Feng J, et al. Comparison on the Antibody Response and Influenced Factors of Hepatitis B Vacine Made by Recombinant Dexyribonucleic Acid Techniques among Adults. Zhong Guo Yi Miao Yu Mian Yi 2013; 19(2):142-146
   Google Scholar
• Yan BY, Zhang L, Lv JJ, Liu JY, Feng Y, Xu AQ, Chen SY, Gong XH, Cui FQ, Liang XF. Comparison of the antibody response and related influencing factors after primary immunization by 10 μg hepatitis B vaccine made from recombinant DNA techniques in saccharomyces and hansenula polymorpha among adults. Zhong Hua Liu Xing Bing Xue Za Zhi 2012; 33(9):988-989; PMID:23297469
   PubMedGoogle Scholar
• Jacques P, Moens G, Desomebere I, Dewijngaert J, Leroux-Roels G, Wettendorff M, Thoelen S. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine 2002 Nov 1; 20(31-32):3644-9; PMID:12399191; http://dx.doi.org/10.1016/S0264-410X(02)00397-3
   PubMed Web of Science ®Google Scholar
• Surquin M, Tielemans CL, Kulcsár I, Ryba M, Vörös P, Mat O, Treille S, Dhaene M, Stolear JC, Kuriyakose SO, et al. Rapid, enhanced and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine. Kidney Int 2010 Feb; 77(3):247-55; PMID:19940840; http://dx.doi.org/10.1038/ki.2009.454
   PubMed Web of Science ®Google Scholar
• Chou HY, Lin XZ, Pan WY, Chang CM, Lin TY, Shen HH, Tao MH. Hydrogel-delivered GM-CSF overcomes nonresponsiveness to hepatitis B vaccine through the recruitment and activation of dendritic cells. J Immunol 2010 Nov 1; 185(9): 5468-75; PMID:20889541; http://dx.doi.org/10.4049/jimmunol.1001875
   PubMed Web of Science ®Google Scholar
• Roukens AH, Visser LG. Hepatitis B vaccination strategy in vaccine low- and non-responders: a matter of quntity of quality? Human Vaccine 2011; 7:6, 654-657; PMID:21508674; http://dx.doi.org/10.4161/hv.7.1.14924
   PubMed Web of Science ®Google Scholar
• Graven DE, Awdeh ZL, Kunches LM, Yunis EJ, Dienstag JL, Werner BG, Polk BF, Syndman DR, Platt R, Crumpacker CS, et al. Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetric typings. Ann Intern Med 1986 Sep; 105(3):356-60; PMID:2943202
   PubMed Web of Science ®Google Scholar
• Golwater PN. Randomized, comparative trial of 20 micrograms vs 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders. Vaccine 1997; 15(4):353-6; PMID:9141204; http://dx.doi.org/10.1016/S0264-410X(96)00202-2
   PubMed Web of Science ®Google Scholar
• Kim MJ, Nafziger AN, Harro CD, Keyserling HL, Ramsey KM, Drusano GL, Bertino JS Jr. Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response. Vaccine 2003; 21(11-12):1174-9; PMID:12559795; http://dx.doi.org/10.1016/S0264-410X(02)00626-6
   PubMed Web of Science ®Google Scholar
• Clemens R, Sänger R, Kruppenbacher J, Höbel W, Stanbury W, Bock HL, Jilg W. Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule—results of a post-marketing surveillance. Vaccine 1997; 15(4):349-52; PMID:9141203; http://dx.doi.org/10.1016/S0264-410X(96)00205-8
   PubMed Web of Science ®Google Scholar
• Craven DE, Awdeh ZL, Kunches LM, Yunis EJ, Dienstag JL, Werner BG, Polk BF, Syndman DR, Platt R, Crumpacker CS, et al. Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings. Ann Intern Med 1986; 105(3):356-60; PMID:2943202; http://dx.doi.org/10.7326/0003-4819-105-3-356
   PubMed Web of Science ®Google Scholar
• Kim MJ, Nafziger AN, Harro CD, Keyserling HL, Ramsey KM, Drusano GL, Bertino JS Jr. Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response. Vaccine 2003 Mar 7; 21(11-12):1174-9; PMID:12559795; http://dx.doi.org/10.1016/S0264-410X(02)00626-6
   PubMed Web of Science ®Google Scholar
• Bertino JS Jr, Tirrell P, Greenberg RN, Keyserling HL, Poland GA, Gump D, Kumar ML, Ramsey K. A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre-S2 particles for revaccination of healthy adult nonresponders. J Infect Dis 1997; 175:678-81; PMID:9041342; http://dx.doi.org/10.1093/infdis/175.3.678
   PubMed Web of Science ®Google Scholar
• Weissman JY, Tsuchiyose MM, Tong MJ, Co R, Chin K, Ettenger RB. Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. JAMA 1988; 260(12):1734-8; PMID:2970557; http://dx.doi.org/10.1001/jama.1988.03410120080031
   PubMed Web of Science ®Google Scholar
• Gesemann M, Scheiermann N. Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence. Vaccine 1995 Apr; 13(5):443-7; PMID:7639012; http://dx.doi.org/10.1016/0264-410X(94)00010-K
   PubMed Web of Science ®Google Scholar
• Jilg W, Schmidt M, Deinhardt F. Decline of anti-HBs after hepatitis B vaccination and timing of revaccination. Lancet 1990 Jan 20; 335(8682):173-4; PMID:1967468; http://dx.doi.org/10.1016/0140-6736(90)90050-F
   PubMed Web of Science ®Google Scholar
• Chiara F, Bartolucci GB, Cattai M, Piazza A, Nicolli A, Buja A, Trevisan A. Hepatitis B vaccination of adolescents: significance of non-protective antibodies. Vaccine 2013 Dec; 32(1):62-8; PMID:24188755; http://dx.doi.org/10.1016/j.vaccine.2013.10.074
   PubMed Web of Science ®Google Scholar
• Hadler SC, Margolis HS. Hepatitis B immunization:vaccine types, efficacy and indications for immunization. Curr Clin Top Infect Dis 1992; 12:282-308; PMID:1386520
   PubMedGoogle Scholar
• Hollinger FB. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines and vaccine protocol recommendations. Am J Med 1989; 87:36-40; PMID:2528297; http://dx.doi.org/10.1016/0002-9343(89)90530-5
   PubMed Web of Science ®Google Scholar
• Zhou W, Bi J, Janson JC, Li Y, Huang Y, Zhang Y, Su Z. Molecular characterization of recombinant Hepatitis B surface antigen from Chinese hamster ovary and Hansenula polymorpha cells by high-performance size exclusion chromatography and multi-angle laser light scattering. J Chromatogr B 2006; 838:71-7; PMID:16757217; http://dx.doi.org/10.1016/j.jchromb.2006.03.064
   PubMed Web of Science ®Google Scholar
• Sato Y, Ishikawa N, Takagi T. High-performance size-exclusion chromatography and molar mass measurement by low-angle laser light scattering of recombinant yeast-derived human hepatitis B virus surface antigen vaccine particles. J Chromatogr 1990 May 16; 507:25-31; PMID:2380294; http://dx.doi.org/10.1016/S0021-9673(01)84177-7
   PubMed Web of Science ®Google Scholar
• Ren GF, Zhang YM, Ruan WQ, Yang DA, Mei YF, Ping LH, et al. High level expression of hepatitis B virus surface antigen in transformed in transformed Chinese hamster ovary (CHO) cell line and immunogenicity of purified product in mice. Chin J Virol 1987; 3(4):313-20
   Google Scholar
• Diminisky D, Schirmbeeck R, Reimann J. Comparison between hepatitis B surface anigen (HBsAg) particles derived from mammalian cell (CHO) and yeast cells (Hansenular polymorpha): composition, structure and immunogenicity. Vaccine 1997; 15(6/7):637-47; PMID:9178464; http://dx.doi.org/10.1016/S0264-410X(96)00239-3
   PubMed Web of Science ®Google Scholar
• Struve J, Aronsson B, Frenning B, Forsgren M, Weiland O. Seroconversion after additional vaccine doses to non-responders to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccine. Scand J Infect Dis 1994; 26(4):468-70; PMID:7984980; http://dx.doi.org/10.3109/00365549409008621
   PubMed Web of Science ®Google Scholar
• Zhou B, Coorperative Meta-Analysis Group of China Obesity Task Force. Predictive values of body mass index and waist circumference to risk factors of related diseases in Chinese population. Zhuanghua Liu Xing Bing Xue Za Zhi 2002 Feb; 23(1):5-10; PMID:12015100
   PubMedGoogle Scholar